IMBRASE is a symptom assessment protocol and management algorithm for patients with advanced or metastatic melanoma who are receiving immunotherapy drug treatment. It follows the patients proactively and manages their care in a tailored manner, determined by patient characteristics and risk level.
Prior to the IMBRASE program, the strategy for monitoring melanoma patients was reactive, where patients would speak with a number of different nurses throughout their care episode and receive multiple assessments and advice regarding management of their symptoms and side effects.
The program has resulted in a reduction in Emergency Department visits for high-risk patients. It has improved patient safety, responsiveness, access to care, and timely intervention.
To learn more about the Quality and Innovation (QI) Awards, visit http://www.cqco.ca/awards